Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroSigma

Full company profile

uuid0002g1a

Namestring
NeuroSigma
Legal namestring
NeuroSigma, Inc.
Websiteurl
neurosigma.com
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation devices, pediatric ADHD treatment, trigeminal nerve stimulation, bioelectronic medicine, medical device
Industry4 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALAEAF
Child & Adolescent Behavioral Health Teletherapy Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Monarch eTNS Device Sales
TypeHardware Sales
Description

NeuroSigma generates revenue from the sale of its Monarch eTNS medical device system for pediatric ADHD treatment. The device is available by prescription only. Pilot commercialization validated strong market demand with over 1,000 devices and 100,000 patches dispensed in the U.S. The second-generation device is scheduled for mass production and U.S. launch in Q1 2026.

mpo-mag.com
2Patches and Consumables
TypeHardware Sales
Description

Over 100,000 patches have been dispensed alongside Monarch eTNS devices, indicating a recurring consumables revenue stream associated with device usage.

mpo-mag.com
3Licensing and Technology Licensing
TypeLicensing Royalties
Description

NeuroSigma licenses its TNS technology to third parties, including a significant China licensing transaction with Ignis Therapeutics for ADHD applications (January 2022). The company is the exclusive worldwide licensee of UCLA's TNS intellectual property portfolio.

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others
Pricing details1 tier
1Monarch eTNS System (prescription device)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Device is available by prescription only for pediatric ADHD patients ages 7-12. Specific pricing not publicly disclosed. CMS HCPCS codes have been obtained for reimbursement purposes.

mpo-mag.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Monarch eTNS System
Description

The Monarch eTNS System is the company's flagship FDA-cleared medical device for treating pediatric ADHD. It is indicated as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medications. The device uses external trigeminal nerve stimulation and is intended for use during sleep under caregiver supervision.

neurosigma.com
Core offering1 text field

NeuroSigma develops and commercializes the Monarch eTNS System, an FDA-cleared wearable medical device that delivers non-invasive external Trigeminal Nerve Stimulation (eTNS) for the treatment of pediatric ADHD in patients ages 7-12 who are not currently on prescription ADHD medications. The device is used at home during sleep under caregiver supervision, and the company also licenses its underlying TNS technology platform for additional neurological and psychiatric indications including epilepsy, depression, autism spectrum disorder, and PTSD.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • ADHD symptom reduction demonstrated statistically significant on ADHD-RS scale in double-blind RCT (McGough et al., 2019)
+4 more records
Product and service4 records
1Monarch eTNS System
CategoryNeuromodulation Medical Device
Description

The Monarch eTNS (external Trigeminal Nerve Stimulation) System is an FDA-cleared wearable medical device indicated as a monotherapy for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications. The device delivers gentle, external electrical pulses to stimulate the trigeminal nerve and is intended for home use during sleep under caregiver supervision.

2Monarch eTNS System (Second Generation)
CategoryNeuromodulation Medical Device
Description

Second-generation Monarch eTNS System with improved design for treatment of pediatric ADHD. Received FDA clearance in January 2024 and officially launched in November 2025 following successful pilot commercialization. Manufactured by Armstrong Asia in Singapore, with high-volume manufacturing established via a December 2025 investment.

3Monarch eTNS Patches
CategoryConsumables / Accessories
Description

Disposable electrode patches used with the Monarch eTNS System during treatment sessions. Over 100,000 patches have been dispensed alongside devices during the pilot commercialization program, serving as a recurring consumables component of the system.

4TNS Technology Licensing
CategoryTechnology Licensing
Description

Licensing of NeuroSigma's proprietary trigeminal nerve stimulation (TNS) technology platform to third parties for development and commercialization in specific indications and territories. Notable licensing transactions include a deal with Ignis Therapeutics for ADHD applications in China.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Armstrong Asia
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-15
Description

Armstrong Asia, based in Singapore, serves as the manufacturing partner for NeuroSigma's second-generation Monarch eTNS device. This partnership enables high-volume scalable production of the device for pediatric ADHD treatment. First units expected to be delivered in March 2026. The manufacturing partnership was part of a $1 million investment led by Checkmate Capital.

latimes.com
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2023-01-31
Description

Data360 is NeuroSigma's strategic digital marketing partner, providing digital marketing services to drive demand generation and customer acquisition for the Monarch eTNS System. Announced in January 2023.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-04-07
Description

King's College London received MHRA approval to commence the largest clinical trial of eTNS for pediatric ADHD to date (April 2022). King's College London completed enrollment in a clinical trial of NeuroSigma's Monarch eTNS System for ADHD (January 2025). Early clinical experience with eTNS for epilepsy also conducted at King's College London.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-25
Description

Ignis Therapeutics licensed NeuroSigma's eTNS technology for ADHD applications in China in a significant China licensing transaction. This represents a major international licensing deal that expands the geographic reach of NeuroSigma's TNS technology in the Chinese market.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-06-14
Description

KT Corporation and NeuroSigma announced a strategic digital health partnership in June 2021, combining NeuroSigma's TNS technology with KT's digital health capabilities to explore collaborative opportunities in digital health solutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Trigeminal nerve stimulation (TNS) was invented at UCLA, and NeuroSigma is the exclusive worldwide licensee of UCLA's intellectual property portfolio related to this technology. NeuroSigma conducts ongoing clinical research in collaboration with UCLA, including a clinical trial of Monarch eTNS for ADHD in children with fetal alcohol syndrome (announced April 2025).

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

electroCore develops non-invasive vagus nerve stimulation (nVNS) devices such as gammaCore for headache and epilepsy indications. It is the most direct peer to NeuroSigma given its non-invasive external neurostimulation approach targeting overlapping neurologic conditions via a similar hardware-and-electrode model.

TypeDirect peer
Description

Akili Interactive developed EndeavorRx, the first FDA-cleared prescription digital therapeutic for pediatric ADHD. It directly competes with NeuroSigma for the same patient population and prescriber channel with a non-drug alternative ADHD treatment, though delivered as software rather than hardware.

TypeBroad incumbent
Description

LivaNova markets VNS Therapy, an implanted vagus nerve stimulation system for drug-resistant epilepsy and treatment-resistant depression. Comparable as an established neuromodulation incumbent targeting overlapping indications (epilepsy, depression) that NeuroSigma is pursuing non-invasively.

TypeBroad incumbent
Description

NeuroPace offers the RNS System, a closed-loop responsive neurostimulation implant for refractory epilepsy. Comparable as a neuromodulation company targeting drug-resistant epilepsy with FDA-cleared neurostim hardware, though using an invasive implanted device versus NeuroSigma's external approach.

TypeBroad incumbent
Description

Inspire Medical Systems commercializes an implantable neurostim device for obstructive sleep apnea. Comparable as a publicly traded neurostimulation hardware company with an FDA-cleared device treating a chronic neurologic/sleep condition via electrical stimulation.

TypeBroad incumbent
Description

Medtronic operates one of the largest neuromodulation businesses globally, including deep brain stimulation, spinal cord stimulation, and targeted drug delivery systems. Comparable as a broad incumbent in implantable neurostimulation across overlapping conditions (epilepsy, movement disorders, psychiatric).

TypeBroad incumbent
Description

Abbott's Neuromodulation division offers Proclaim DRG, Infinity DBS, and Proclaim spinal cord stimulation systems for chronic pain and movement disorders. Comparable as a large incumbent with FDA-cleared neurostim hardware for chronic neurologic conditions.

TypeEmerging player
Description

Cognoa develops FDA-cleared diagnostic and therapeutic digital health products for pediatric neurodevelopmental conditions including autism. Comparable as a pediatric-focused neurodevelopmental technology company pursuing FDA pathways for childhood behavioral conditions, though in digital rather than neurostim hardware.

TypeBroad incumbent
Description

Boston Scientific operates a significant neuromodulation portfolio (Vercise DBS, WaveWriter spinal cord stim, Precision Spectra). Comparable as a broad medical device incumbent in implantable neurostimulation across chronic neurologic indications.

TypeEmerging player
Description

Click Therapeutics develops prescription digital therapeutics across CNS indications including ADHD and depression. Comparable as an emerging player pursuing FDA-cleared software-based treatments for the same neuropsychiatric conditions NeuroSigma targets with hardware.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroSigma

Neuromodulation Medical Devicesneurosigma.com

NeuroSigma firmographics

Firmographics
Name
NeuroSigma
Legal name
NeuroSigma, Inc.
Website
https://neurosigma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

NeuroSigma industry classification

Industry
Product category
Neuromodulation Medical Devices
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALAEAF
Child & Adolescent Behavioral Health Teletherapy Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Neuromodulation devices
  • Pediatric ADHD treatment
  • Trigeminal nerve stimulation
  • Bioelectronic medicine
  • Medical device

Where NeuroSigma is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NeuroSigma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Monarch eTNS Device Sales: NeuroSigma generates revenue from the sale of its Monarch eTNS medical device system for pediatric ADHD treatment. The device is available by prescription only. Pilot commercialization validated strong market demand with over 1,000 devices and 100,000 patches dispensed in the U.S. The second-generation device is scheduled for mass production and U.S. launch in Q1 2026.
  2. Patches and Consumables: Over 100,000 patches have been dispensed alongside Monarch eTNS devices, indicating a recurring consumables revenue stream associated with device usage.
  3. Licensing and Technology Licensing: NeuroSigma licenses its TNS technology to third parties, including a significant China licensing transaction with Ignis Therapeutics for ADHD applications (January 2022). The company is the exclusive worldwide licensee of UCLA's TNS intellectual property portfolio.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goMonarch eTNS System (prescription device)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

NeuroSigma product offering

Product offering

Core offering

NeuroSigma develops and commercializes the Monarch eTNS System, an FDA-cleared wearable medical device that delivers non-invasive external Trigeminal Nerve Stimulation (eTNS) for the treatment of pediatric ADHD in patients ages 7-12 who are not currently on prescription ADHD medications. The device is used at home during sleep under caregiver supervision, and the company also licenses its underlying TNS technology platform for additional neurological and psychiatric indications including epilepsy, depression, autism spectrum disorder, and PTSD.

Differentiator

Problem solved

Functional benefit

Brands

  • Monarch eTNS System: The Monarch eTNS System is the company's flagship FDA-cleared medical device for treating pediatric ADHD. It is indicated as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medications. The device uses external trigeminal nerve stimulation and is intended for use during sleep under caregiver supervision.

Products and services

  • Monarch eTNS System The Monarch eTNS (external Trigeminal Nerve Stimulation) System is an FDA-cleared wearable medical device indicated as a monotherapy for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications. The device delivers gentle, external electrical pulses to stimulate the trigeminal nerve and is intended for home use during sleep under caregiver supervision.
  • Monarch eTNS System (Second Generation) Second-generation Monarch eTNS System with improved design for treatment of pediatric ADHD. Received FDA clearance in January 2024 and officially launched in November 2025 following successful pilot commercialization. Manufactured by Armstrong Asia in Singapore, with high-volume manufacturing established via a December 2025 investment.
  • Monarch eTNS Patches Disposable electrode patches used with the Monarch eTNS System during treatment sessions. Over 100,000 patches have been dispensed alongside devices during the pilot commercialization program, serving as a recurring consumables component of the system.
  • TNS Technology Licensing Licensing of NeuroSigma's proprietary trigeminal nerve stimulation (TNS) technology platform to third parties for development and commercialization in specific indications and territories. Notable licensing transactions include a deal with Ignis Therapeutics for ADHD applications in China.

Quantifiable outcome

  • ADHD symptom reduction demonstrated statistically significant on ADHD-RS scale in double-blind RCT (McGough et al., 2019)
  • +4 more outcomes

Companies that use NeuroSigma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

NeuroSigma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NeuroSigma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, supporting and major.

  • Armstrong AsiacoreOEM/ Whitelabel/ Licensing Partner · 15 December 2025Armstrong Asia, based in Singapore, serves as the manufacturing partner for NeuroSigma's second-generation Monarch eTNS device. This partnership enables high-volume scalable production of the device for pediatric ADHD treatment. First units expected to be delivered in March 2026. The manufacturing partnership was part of a $1 million investment led by Checkmate Capital.
  • Data360supportingGTM or Marketing Partner · 31 January 2023Data360 is NeuroSigma's strategic digital marketing partner, providing digital marketing services to drive demand generation and customer acquisition for the Monarch eTNS System. Announced in January 2023.
  • King's College LondonmajorStrategic or Co-development Partner · 7 April 2022King's College London received MHRA approval to commence the largest clinical trial of eTNS for pediatric ADHD to date (April 2022). King's College London completed enrollment in a clinical trial of NeuroSigma's Monarch eTNS System for ADHD (January 2025). Early clinical experience with eTNS for epilepsy also conducted at King's College London.
  • Ignis TherapeuticsmajorOEM/ Whitelabel/ Licensing Partner · 25 January 2022Ignis Therapeutics licensed NeuroSigma's eTNS technology for ADHD applications in China in a significant China licensing transaction. This represents a major international licensing deal that expands the geographic reach of NeuroSigma's TNS technology in the Chinese market.
  • KT CorporationsupportingStrategic or Co-development Partner · 14 June 2021KT Corporation and NeuroSigma announced a strategic digital health partnership in June 2021, combining NeuroSigma's TNS technology with KT's digital health capabilities to explore collaborative opportunities in digital health solutions.
  • UCLA (University of California, Los Angeles)coreStrategic or Co-development PartnerTrigeminal nerve stimulation (TNS) was invented at UCLA, and NeuroSigma is the exclusive worldwide licensee of UCLA's intellectual property portfolio related to this technology. NeuroSigma conducts ongoing clinical research in collaboration with UCLA, including a clinical trial of Monarch eTNS for ADHD in children with fetal alcohol syndrome (announced April 2025).

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

NeuroSigma competitors and assessment

Company assessment

Direct peers

  • electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) devices such as gammaCore for headache and epilepsy indications. It is the most direct peer to NeuroSigma given its non-invasive external neurostimulation approach targeting overlapping neurologic conditions via a similar hardware-and-electrode model.
  • Akili Interactive: Akili Interactive developed EndeavorRx, the first FDA-cleared prescription digital therapeutic for pediatric ADHD. It directly competes with NeuroSigma for the same patient population and prescriber channel with a non-drug alternative ADHD treatment, though delivered as software rather than hardware.

Broad incumbents

  • LivaNova: LivaNova markets VNS Therapy, an implanted vagus nerve stimulation system for drug-resistant epilepsy and treatment-resistant depression. Comparable as an established neuromodulation incumbent targeting overlapping indications (epilepsy, depression) that NeuroSigma is pursuing non-invasively.
  • NeuroPace: NeuroPace offers the RNS System, a closed-loop responsive neurostimulation implant for refractory epilepsy. Comparable as a neuromodulation company targeting drug-resistant epilepsy with FDA-cleared neurostim hardware, though using an invasive implanted device versus NeuroSigma's external approach.
  • Inspire Medical Systems: Inspire Medical Systems commercializes an implantable neurostim device for obstructive sleep apnea. Comparable as a publicly traded neurostimulation hardware company with an FDA-cleared device treating a chronic neurologic/sleep condition via electrical stimulation.
  • Medtronic: Medtronic operates one of the largest neuromodulation businesses globally, including deep brain stimulation, spinal cord stimulation, and targeted drug delivery systems. Comparable as a broad incumbent in implantable neurostimulation across overlapping conditions (epilepsy, movement disorders, psychiatric).
  • Abbott: Abbott's Neuromodulation division offers Proclaim DRG, Infinity DBS, and Proclaim spinal cord stimulation systems for chronic pain and movement disorders. Comparable as a large incumbent with FDA-cleared neurostim hardware for chronic neurologic conditions.
  • Boston Scientific: Boston Scientific operates a significant neuromodulation portfolio (Vercise DBS, WaveWriter spinal cord stim, Precision Spectra). Comparable as a broad medical device incumbent in implantable neurostimulation across chronic neurologic indications.

Emerging players

  • Cognoa: Cognoa develops FDA-cleared diagnostic and therapeutic digital health products for pediatric neurodevelopmental conditions including autism. Comparable as a pediatric-focused neurodevelopmental technology company pursuing FDA pathways for childhood behavioral conditions, though in digital rather than neurostim hardware.
  • Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across CNS indications including ADHD and depression. Comparable as an emerging player pursuing FDA-cleared software-based treatments for the same neuropsychiatric conditions NeuroSigma targets with hardware.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuroSigma social profiles

Digital presence

NeuroSigma compliance and trust

Trust signal

Compliance4 records

NeuroSigma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroSigma leadership team

Management profile

Number of profiles

Profiles7 records

NeuroSigma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NeuroSigma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroSigma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroSigma

What does NeuroSigma do?

NeuroSigma develops and commercializes the Monarch eTNS System, an FDA-cleared wearable medical device that delivers non-invasive external Trigeminal Nerve Stimulation (eTNS) for the treatment of pediatric ADHD in patients ages 7-12 who are not currently on prescription ADHD medications. The device is used at home during sleep under caregiver supervision, and the company also licenses its underlying TNS technology platform for additional neurological and psychiatric indications including epilepsy, depression, autism spectrum disorder, and PTSD.

Is NeuroSigma a public or private company?

NeuroSigma is a private company. It is classified as venture growth investor backed and is currently operating.

When was NeuroSigma founded?

NeuroSigma was founded in 2011. It employs 1 to 10 people.

Where is NeuroSigma based?

NeuroSigma is headquartered in Los Angeles, United States, in the North America region.

How does NeuroSigma make money?

Three revenue lines are on record. Monarch eTNS Device Sales are the primary driver. The others are patches and Consumables and licensing and Technology Licensing.

Who are NeuroSigma's main competitors?

Direct peers on record are electroCore and Akili Interactive. Broad incumbents are LivaNova, NeuroPace, Inspire Medical Systems, Medtronic, Abbott and Boston Scientific. Emerging players are Cognoa and Click Therapeutics.

Does NeuroSigma have an API?

No public API is recorded for NeuroSigma.

What industry is NeuroSigma in?

NeuroSigma's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAEAJ, Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching). Its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeFirefly Neuroscience Reports 373% Year-Over-Year Increase in Pediatric ADHD Scan Volume for Evoke Platform | AIFF Stock NewsFirefly Neuroscience reported a 373% year-over-year increase in commercial use of its Evoke platform for pediatric ADHD scans. The company holds over 200,000 proprietary EEG/ERP scans and is partnering with NeuroSigma to distribute the Monarch eTNS treatment.GlobeNewswireFirefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion AcceleratesFirefly Neuroscience reported a 373% year-over-year increase in commercial utilization of its Evoke platform for pediatric ADHD patients. The company also noted a proprietary dataset of over 200,000 scans and is expanding cross-sell with NeuroSigma's Monarch eTNS treatment.Medical Device NetworkFirefly to offer NeuroSigma’s non-drug ADHD device to cliniciansFirefly Neuroscience partnered with NeuroSigma to offer the FDA-cleared Monarch eTNS device to clinicians using its Evoke platform. The device provides non-drug treatment for pediatric ADHD, with second-generation shipments in July 2026 and a waitlist of over 1,500 patients. Firefly will introduce the therapy to its clinician network, while NeuroSigma supplies training and fulfillment.BioSpaceNeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHDNeuroSigma launched U.S. sales of its second-generation Monarch eTNS System for pediatric ADHD on July 21, 2026. The device, an FDA-cleared non-drug treatment, features a color screen, simplified interface, and integrated rechargeable battery, with a waitlist of over 1,500 patients, caregivers, and providers.Medical NewsStudy Questions Benefit of FDA-Cleared Device for ADHDA phase IIb trial conducted in England found that the Monarch external trigeminal nerve stimulation (eTNS) device was no more effective than a sham treatment for reducing ADHD symptoms in children and adolescents. The study, published in Nature Medicine by researchers from King's College London, contradicts earlier FDA-cleared findings and has prompted the U.S. FDA to review the new data. NeuroSigma, the manufacturer of the device, has not yet responded to the findings regarding its product's efficacy.Los Angeles TimesNeuroSigma Invests $1 Million to Scale Manufacturing for ADHD Medical DeviceNeuroSigma, a Los Angeles-based bioelectronics company, completed a $1-million investment to establish a high-volume manufacturing line for its second-generation Monarch external Trigeminal Nerve Stimulation device for pediatric ADHD treatment, with the device scheduled for launch in Q1 2026. The investment was made in partnership with Singapore-based Armstrong Asia and led by Pasadena-based Checkmate Capital as part of a collaboration focused on cross-border life sciences transactions. The first-generation Monarch eTNS System was the first wearable medical device to receive FDA clearance as a drug-free treatment for ADHD, offering an alternative to stimulant medications.GlobeNewswireNeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® DeviceNeuroSigma, a Los Angeles-based bioelectronics company, announced completion of a $1 million investment into a high-volume manufacturing line for its second-generation Monarch eTNS device for pediatric ADHD, with first commercial units expected in March 2026. Singapore-based Armstrong Asia has been selected as the manufacturing partner, and Checkmate Capital led the investment as part of a strategic partnership formed under a July 2025 MOU. The company successfully completed a pilot commercialization program in November 2025, having dispensed over 1,000 Monarch devices and 100,000 daily disposable patches, and is now preparing for a late Q1 2026 launch based on strong market demand.Business InsiderNeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® DeviceNeuroSigma, a Los Angeles-based bioelectronics company, announced completion of a $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation device for treating pediatric ADHD. Singapore-based Armstrong Asia has been selected as the manufacturing partner, with the investment led by Checkmate Capital, and first commercial units are scheduled for delivery in March 2026. The second-generation Monarch eTNS device is expected to launch in late Q1 2026 following a successful pilot program that dispensed over 1,000 devices.openPR.comPeripheral Neurostimulator System Market Exclusive Report on Current Trends and Future InsightsInsightAce Analytic Pvt. Ltd. announced the publication of a market research report forecasting the global peripheral neurostimulator system market to reach over USD 1994.51 Million by 2031 with a CAGR of 9.24%. The report highlights key industry players such as Boston Scientific Corporation, B. Braun SE, and NeuroSigma Inc., noting that growth is driven by technological advancements and an aging population despite high costs limiting accessibility.